Status:
ACTIVE_NOT_RECRUITING
Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.
Lead Sponsor:
Laboratoires Thea
Conditions:
Glaucoma
Ocular Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The study purpose is to evaluate the safety of T4090.
Eligibility Criteria
Inclusion
- Informed consent dated and signed.
- Both eyes diagnosed open-angle glaucoma or ocular hypertension
Exclusion
- History of trauma, infection, clinically significant inflammation within the previous 6 months
- Known or suspected hypersensitivity to one of the components of the Investigational Medicinal Product(s)
- Pregnancy or breast-feeding
Key Trial Info
Start Date :
July 5 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT05389267
Start Date
July 5 2022
End Date
December 31 2024
Last Update
February 7 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dr EL-HARAZI
Glendale, California, United States, 91204